| Mutation‐enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera A Tefferi, P Guglielmelli, TL Lasho, G Coltro, CM Finke, GG Loscocco, ... British journal of haematology 189 (2), 291-302, 2020 | 205 | 2020 |
| Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial T Barbui, AM Vannucchi, V De Stefano, A Masciulli, A Carobbio, A Ferrari, ... The Lancet Haematology 8 (3), e175-e184, 2021 | 116 | 2021 |
| Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study AM Vannucchi, B Sordi, A Morettini, C Nozzoli, L Poggesi, F Pieralli, ... Leukemia 35 (4), 1121-1133, 2021 | 83 | 2021 |
| JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis P Guglielmelli, GG Loscocco, C Mannarelli, E Rossi, F Mannelli, ... Blood cancer journal 11 (12), 199, 2021 | 71 | 2021 |
| Splanchnic vein thromboses associated with myeloproliferative neoplasms: an international, retrospective study on 518 cases E Sant'Antonio, P Guglielmelli, L Pieri, M Primignani, ML Randi, ... American journal of hematology 95 (2), 156-166, 2020 | 67 | 2020 |
| Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera A Carobbio, AM Vannucchi, V De Stefano, A Masciulli, P Guglielmelli, ... Blood cancer journal 12 (2), 28, 2022 | 57 | 2022 |
| Impact of mutational profile on the management of myeloproliferative neoplasms: a short review of the emerging data GG Loscocco, P Guglielmelli, AM Vannucchi OncoTargets and therapy, 12367-12382, 2020 | 57 | 2020 |
| Mutations and thrombosis in essential thrombocythemia P Guglielmelli, N Gangat, G Coltro, TL Lasho, GG Loscocco, CM Finke, ... Blood cancer journal 11 (4), 77, 2021 | 39 | 2021 |
| Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms V De Stefano, A Carobbio, V Di Lazzaro, P Guglielmelli, A Iurlo, ... Blood cancer journal 8 (3), 25, 2018 | 38 | 2018 |
| Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: a multicenter study involving 1607 patients GG Loscocco, P Guglielmelli, N Gangat, E Rossi, C Mannarelli, S Betti, ... American journal of hematology 96 (11), 1472-1480, 2021 | 33 | 2021 |
| Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera T Barbui, AM Vannucchi, V De Stefano, A Carobbio, A Ghirardi, G Carioli, ... NEJM evidence 2 (6), EVIDoa2200335, 2023 | 29 | 2023 |
| ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera P Guglielmelli, G Coltro, F Mannelli, G Rotunno, GG Loscocco, ... Blood Advances 6 (9), 2927-2931, 2022 | 26 | 2022 |
| Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives GG Loscocco, AM Vannucchi International Journal of Hematology 115 (5), 626-644, 2022 | 26 | 2022 |
| Secondary hemophagocytic lymphohistiocytosis, HScore and COVID-19. GG Loscocco International Journal of Hematology, 2020 | 25 | 2020 |
| Classical Philadelphia-negative myeloproliferative neoplasms (MPNs): A continuum of different disease entities G Coltro, GG Loscocco, AM Vannucchi International Review of Cell and Molecular Biology 365, 1-69, 2021 | 23 | 2021 |
| Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia F Farrukh, P Guglielmelli, GG Loscocco, A Pardanani, CA Hanson, ... American journal of hematology 97 (2), E35-E37, 2022 | 22 | 2022 |
| A globally applicable “triple A” risk model for essential thrombocythemia based on A ge, A bsolute neutrophil count, and A bsolute lymphocyte count A Tefferi, GG Loscocco, F Farrukh, N Szuber, F Mannelli, A Pardanani, ... American journal of hematology 98 (12), 1829-1837, 2023 | 17 | 2023 |
| Integration of molecular information in risk assessment of patients with myeloproliferative neoplasms GG Loscocco, G Coltro, P Guglielmelli, AM Vannucchi Cells 10 (8), 1962, 2021 | 16 | 2021 |
| Germline transmission of LNKE208Q variant in a family with myeloproliferative neoplasms GG Loscocco, C Mannarelli, A Pacilli, T Fanelli, G Rotunno, F Gesullo, ... American journal of hematology 91 (9), E356, 2016 | 15 | 2016 |
| Myeloid sarcoma: more and less than a distinct entity GG Loscocco, AM Vannucchi Annals of Hematology 102 (8), 1973-1984, 2023 | 14 | 2023 |
Paola GuglielmelliUniversità degli studi di FirenzeVerified email at unifi.it
